Literature DB >> 34433915

The prefrontal cortex and neurosurgical treatment for intractable OCD.

Steven A Rasmussen1,2, Wayne K Goodman3.   

Abstract

Over the past two decades, circuit-based neurosurgical procedures have gained increasing acceptance as a safe and efficacious approach to the treatment of the intractable obsessive-compulsive disorder (OCD). Lesions and deep brain stimulation (DBS) of the longitudinal corticofugal white matter tracts connecting the prefrontal cortex with the striatum, thalamus, subthalamic nucleus (STN), and brainstem implicate orbitofrontal, medial prefrontal, frontopolar, and ventrolateral cortical networks in the symptoms underlying OCD. The highly parallel distributed nature of these networks may explain the relative lack of adverse effects observed following surgery. Additional pre-post studies of cognitive tasks in more surgical patients are needed to confirm the role of these networks in OCD and to define therapeutic responses to surgical intervention.
© 2021. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Entities:  

Mesh:

Year:  2021        PMID: 34433915      PMCID: PMC8616947          DOI: 10.1038/s41386-021-01149-5

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  109 in total

1.  Cognitive and behavioral treatments for anxiety disorders: a review of meta-analytic findings.

Authors:  Brett J Deacon; Jonathan S Abramowitz
Journal:  J Clin Psychol       Date:  2004-04

Review 2.  Pharmacological treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Michael H Bloch
Journal:  Psychiatr Clin North Am       Date:  2014-07-24

Review 3.  Practice guideline for the treatment of patients with obsessive-compulsive disorder.

Authors:  Lorrin M Koran; Gregory L Hanna; Eric Hollander; Gerald Nestadt; Helen Blair Simpson
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

4.  Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.

Authors:  W K Goodman; L H Price; P L Delgado; J Palumbo; J H Krystal; L M Nagy; S A Rasmussen; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1990-06

5.  Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.

Authors:  Deborah L Ackerman; Sander Greenland
Journal:  J Clin Psychopharmacol       Date:  2002-06       Impact factor: 3.153

Review 6.  A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.

Authors:  T A Pigott; S M Seay
Journal:  J Clin Psychiatry       Date:  1999-02       Impact factor: 4.384

7.  Quality of life in obsessive-compulsive disorder: an evaluation of impairment and a preliminary analysis of the ameliorating effects of treatment.

Authors:  Melissa M Norberg; John E Calamari; Robyn J Cohen; Bradley C Riemann
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

Review 8.  The epidemiology and clinical features of obsessive compulsive disorder.

Authors:  S A Rasmussen; J L Eisen
Journal:  Psychiatr Clin North Am       Date:  1992-12

9.  Mortality Among Persons With Obsessive-Compulsive Disorder in Denmark.

Authors:  Sandra M Meier; Manuel Mattheisen; Ole Mors; Diana E Schendel; Preben B Mortensen; Kerstin J Plessen
Journal:  JAMA Psychiatry       Date:  2016-03       Impact factor: 21.596

10.  The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication.

Authors:  A M Ruscio; D J Stein; W T Chiu; R C Kessler
Journal:  Mol Psychiatry       Date:  2008-08-26       Impact factor: 15.992

View more
  1 in total

Review 1.  Neuromodulation of OCD: A review of invasive and non-invasive methods.

Authors:  Alexandra Kammen; Jonathon Cavaleri; Jordan Lam; Adam C Frank; Xenos Mason; Wooseong Choi; Marisa Penn; Kaevon Brasfield; Barbara Van Noppen; Stuart B Murray; Darrin Jason Lee
Journal:  Front Neurol       Date:  2022-08-09       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.